Pinion Investment Advisors LLC Makes New $276,000 Investment in Eli Lilly and Company $LLY

Key Points

• Pinion Investment Advisors LLC made a new investment in Eli Lilly and Company, purchasing 354 shares valued at approximately $276,000 in the second quarter.
• Wall Street analysts have downgraded Eli Lilly's stock rating, with an average price target set at $948.56, reflecting varying predictions about its future performance.
• Insiders at Eli Lilly have been actively buying shares, including Director J Erik Fyrwald, who purchased 1,565 shares worth over $1 million, increasing his ownership stake in the company.

Pinion Investment Advisors LLC purchased a new position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 354 shares of the company's stock, valued at approximately $276,000.

Other institutional investors also recently bought and sold shares of the company. Hobbs Wealth Management LLC increased its holdings in shares of Eli Lilly and Company by 0.8% in the 1st quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company's stock valued at $1,205,000 after acquiring an additional 12 shares during the last quarter. Hixon Zuercher LLC increased its holdings in shares of Eli Lilly and Company by 0.7% in the 1st quarter. Hixon Zuercher LLC now owns 1,789 shares of the company's stock valued at $1,477,000 after acquiring an additional 12 shares during the last quarter. O Brien Wealth Partners LLC grew its stake in Eli Lilly and Company by 25.5% during the 1st quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock worth $49,000 after buying an additional 12 shares during the last quarter. Ascent Capital Management LLC grew its stake in Eli Lilly and Company by 2.5% during the 1st quarter. Ascent Capital Management LLC now owns 495 shares of the company's stock worth $409,000 after buying an additional 12 shares during the last quarter. Finally, Tennessee Valley Asset Management Partners grew its stake in Eli Lilly and Company by 2.7% during the 1st quarter. Tennessee Valley Asset Management Partners now owns 493 shares of the company's stock worth $407,000 after buying an additional 13 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on LLY shares. Wall Street Zen downgraded Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research note on Saturday, September 20th. JPMorgan Chase & Co. lowered their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating for the company in a research note on Tuesday, September 16th. Deutsche Bank Aktiengesellschaft reduced their price target on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating for the company in a research report on Monday, August 11th. Morgan Stanley reduced their price target on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an "overweight" rating for the company in a research report on Friday, October 3rd. Finally, HSBC boosted their price target on Eli Lilly and Company from $700.00 to $800.00 in a research report on Wednesday, October 1st. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $948.56.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, Director J Erik Fyrwald purchased 1,565 shares of the company's stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the transaction, the director owned 74,578 shares of the company's stock, valued at approximately $47,903,686.74. This represents a 2.14% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Jamere Jackson purchased 200 shares of the company's stock in a transaction that occurred on Friday, August 8th. The shares were acquired at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the transaction, the director directly owned 9,402 shares of the company's stock, valued at $6,013,143.12. This trade represents a 2.17% increase in their position. The disclosure for this purchase can be found here. Insiders bought a total of 4,514 shares of company stock valued at $2,894,841 over the last 90 days. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Trading Up 1.0%

Shares of Eli Lilly and Company stock opened at $854.40 on Friday. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The firm has a market cap of $808.66 billion, a price-to-earnings ratio of 55.84, a price-to-earnings-growth ratio of 1.18 and a beta of 0.47. The business has a fifty day simple moving average of $740.99 and a 200-day simple moving average of $766.49. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $937.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same period in the prior year, the business posted $3.92 earnings per share. Eli Lilly and Company's revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.